TFF Pharmaceuticals Inc TFFP

Healthcare Biotechnology

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

NDAQ:TFFP - Post by User

TFF Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Apr 29, 2024 9:00pm

75 Views

Post# 36013847

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public

NEWS: $TFFP TFF Pharmaceuticals Announces Pricing of $4.8 Million Public OfferingFORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented T...TFFP - TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment